688488.SH
Jiangsu Aidea Pharmaceutical Group Co., Ltd.
SSE · Healthcare · Biotechnology · CN
CNY 12.61
+2.11%Year over year
Reported trailing growth
- Revenue
- +33.8%
- EBITDA
- —
- EBIT
- +129.7%
- EPS
- +72.4%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +43.3%
- EBITDA
- +193.8%
- EBIT
- +129.2%
- Net income
- +86.2%
- EPS
- +85.3%
- Free cash flow
- +63.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026